Eastern Europe diversity should be considered in EU-wide cancer plan

By |september 20th, 2019|cancer, drug innovation, News, Romania, statistics|

Having a pan-European cancer control plan is crucial, but some flexibility should be granted to member states in choosing which aspect to prioritise within the framework, said Linda Gibbs from Pfizer Oncology in an interview with EURACTIV.com.

Komentarji so izklopljeni za Eastern Europe diversity should be considered in EU-wide cancer plan

Discussion heats up over stockpiling of generic drugs under patent protection

By |januar 21st, 2019|drug innovation, EFPIA, generic drugs, generic medicine, News, SPC manufacturing waiver|

The Commission has announced its intention to add a manufacturing waiver to supplementary protection certificates (SPC), as part of its upgraded 2015 Single Market Strategy.

Komentarji so izklopljeni za Discussion heats up over stockpiling of generic drugs under patent protection

The European Commission should shelve its patent law proposal

By |november 30th, 2018|drug approval, drug innovation, drug pricing, News, patent, SPC manufacturing waiver|

The European Commission is considering an initiative that would permanently hobble the continent's economy, writes Jan Fischer.

Komentarji so izklopljeni za The European Commission should shelve its patent law proposal

Greek minister: Effective health and pharma policy needs stronger EU Commission role

By |november 7th, 2018|drug innovation, drug pricing, Greek austerity, Greek crisis, News|

A number of member states want the European Commission’s competences in health and pharma policy to be upgraded in order to face more effectively the rising challenges in the field, Greek health minister Andreas Ksanthos told EURACTIV.com in an interview.

Komentarji so izklopljeni za Greek minister: Effective health and pharma policy needs stronger EU Commission role

New drugs: how much are governments paying for innovation?

By |oktober 10th, 2018|drug innovation, drug pricing, generic drugs, News, Orphan drugs|

The European healthcare sector is divided over the “actual value” EU governments pay for the authorised and partly public-funded novel drugs, compared to medicines already on the market.

Komentarji so izklopljeni za New drugs: how much are governments paying for innovation?

EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

By |julij 3rd, 2018|Big pharma, drug innovation, drug pricing, EFPIA, generic drugs, intellectual property rights, News, Orphan drugs, pharmaceutical companies, SPC manufacturing waiver|

The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.  

Komentarji so izklopljeni za EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

Time to end fragmentation of EU healthcare, experts say

By |maj 8th, 2018|Celgene, drug innovation, drug pricing, EFPIA, News|

Experts are asking for a more collaborative approach in EU healthcare and greater involvement of the European Commission in order to face rising challenges and put patients at the core of decision-making.

Komentarji so izklopljeni za Time to end fragmentation of EU healthcare, experts say

Health expert: Europe should not put its dominant pharma innovation at risk

By |januar 29th, 2018|Adrian Towse, drug innovation, drug pricing, intellectual property rights, News, SPC manufacturing waiver|

The European Union should not create an environment more favourable to generics compared to the innovative pharmaceuticals, as it risks weakening Europe’s overall global strength in pharmaceuticals and in research, Professor Adrian Towse told EURACTIV.com in an interview.

Komentarji so izklopljeni za Health expert: Europe should not put its dominant pharma innovation at risk

Commission reassures ‘worried’ member states on Health Technology Assessment

By |januar 10th, 2018|drug innovation, Health Technology Assessment, Medical devices, News, Vytenis Andriukaitis|

The Commission’s upcoming proposal on Health Technology Assessment (HTA) will focus on clinical aspects and leave member states to decide on economic or ethical parts, a European Commission spokesperson told EURACTIV.com.

Komentarji so izklopljeni za Commission reassures ‘worried’ member states on Health Technology Assessment

Drugs incentives have saved lives in Europe [Sponsored]

By |december 12th, 2017|Big pharma, drug innovation, incentives, Innovation, News, pharma companies|

Without strong incentives to spur continued investment in medical innovation, we cannot hope to ensure the sustainability of European healthcare systems and fulfil the promise of our great union, writes Jan Fischer.

Komentarji so izklopljeni za Drugs incentives have saved lives in Europe [Sponsored]